Medical Device Network on MSN8d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.
Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...
Per the latest update, the Evolut FX+ TAVR system is seeing strong uptake in the United States, with international expansion progressing well. With favorable trial results, Medtronic’s ...
"Medtronic announces two-year trial outcomes of Evolut TAVR" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been ...
Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
Per the latest update, the Evolut FX+ TAVR system is seeing strong uptake in the United States, with international expansion progressing well. With favorable trial results, Medtronic’s development ...
Additional results demonstrated that Evolut TAVR showed the following relative ... which is part of the Cardiovascular Portfolio at Medtronic. "At two years, we continue to see superior valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback